CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). CASI Pharmaceuticals Inc (NASDAQ:CASI) stock performance was -4.79% in last session and finished the day at $1.85. … Continue reading Unusual Volume at bioetch stocks: CASI Pharmaceuticals (NASDAQ:CASI), Codexis (NASDAQ:CDXS), China Biologic Products (NASDAQ:CBPO), Revance Therapeutics (NASDAQ:RVNC), Oncolytics Biotech, (NASDAQ:ONCY)